| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c98babf0d86f960b139cdb7401f3420f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_070ead0dcb90ca2eb0e8a9abf413e7f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aac9cb1917322b2b63f957f3926cb281
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f71a3c992ab45d9b7518839ef8ea055
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1073715686ac18e3d63428c24963b9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e21ac2350bcba9e61a724d7bae27f517 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-20122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-47 |
| filingDate |
2001-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d34394f53921e0ad36f35aee1bba243b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ec0cc288ebae468f0362e6218076665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f30be40480a81e6326e269eafe62b91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d435a83ca64b15aaf061c0d8c72d71f5 |
| publicationDate |
2002-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-02078732-A1 |
| titleOfInvention |
A noval vaccine formulation consisting of dna vaccine inactivated virus |
| abstract |
Disclosed herein is a novel vaccine formulation for prophylatic or therapeutic immunization of vertebrates against infections caused by vertebrate viruses. The said vaccine contains a minimum of two components, one of which is a deoxyribonucleotide (DNA) vaccine comprising of a DNA molecule that encodes a polypeptide of the virus and the other component consisting of inactivated form of the virus. This invention can also be used to develop low cost inactivated virus-based vaccines that contain much lower amount of the said virus than that present in similar vaccines known in the prior art. This invention also relates to a process of producing the said novel vaccine formulation and the use of the said formulation. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109196104-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1593392-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10940196-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109196104-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3443097-A4 |
| priorityDate |
2001-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |